Whole-exome sequencing identifies homozygous mutation in TTI2 in a child with primary microcephaly: a case report.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
15 Feb 2020
Historique:
received: 23 12 2019
accepted: 12 02 2020
entrez: 17 2 2020
pubmed: 18 2 2020
medline: 24 6 2020
Statut: epublish

Résumé

Primary microcephaly is defined as reduced occipital-frontal circumference noticeable before 36 weeks of gestation. Large amount of insults might lead to microcephaly including infections, hypoxia and genetic mutations. More than 16 genes are described in autosomal recessive primary microcephaly. However, the cause of microcephaly remains unclear in many cases after extensive investigations and genetic screening. Here, we described the case of a boy with primary microcephaly who presented to a neurology clinic with short stature, global development delay, dyskinetic movement, strabismus and dysmorphic features. We performed microcephaly investigations and genetic panels. Then, we performed whole-exome sequencing to identify any genetic cause. Microcephaly investigations and genetic panels were negative, but we found a new D317V homozygous mutation in TELOE-2 interacting protein 2 (TTI2) gene by whole-exome sequencing. TTI2 is implicated in DNA damage response and mutation in that gene was previously described in mental retardation, autosomal recessive 39. We described the first French Canadian case with primary microcephaly and global developmental delay secondary to a new D317V homozygous mutation in TTI2 gene. Our report also highlights the importance of TTI2 protein in brain development.

Sections du résumé

BACKGROUND BACKGROUND
Primary microcephaly is defined as reduced occipital-frontal circumference noticeable before 36 weeks of gestation. Large amount of insults might lead to microcephaly including infections, hypoxia and genetic mutations. More than 16 genes are described in autosomal recessive primary microcephaly. However, the cause of microcephaly remains unclear in many cases after extensive investigations and genetic screening.
CASE PRESENTATION METHODS
Here, we described the case of a boy with primary microcephaly who presented to a neurology clinic with short stature, global development delay, dyskinetic movement, strabismus and dysmorphic features. We performed microcephaly investigations and genetic panels. Then, we performed whole-exome sequencing to identify any genetic cause. Microcephaly investigations and genetic panels were negative, but we found a new D317V homozygous mutation in TELOE-2 interacting protein 2 (TTI2) gene by whole-exome sequencing. TTI2 is implicated in DNA damage response and mutation in that gene was previously described in mental retardation, autosomal recessive 39.
CONCLUSIONS CONCLUSIONS
We described the first French Canadian case with primary microcephaly and global developmental delay secondary to a new D317V homozygous mutation in TTI2 gene. Our report also highlights the importance of TTI2 protein in brain development.

Identifiants

pubmed: 32061250
doi: 10.1186/s12883-020-01643-1
pii: 10.1186/s12883-020-01643-1
pmc: PMC7023720
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

58

Références

Genes Cells. 2007 Dec;12(12):1301-4
pubmed: 18076567
Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16595-600
pubmed: 20823249
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Neuron. 2001 Dec 20;32(6):1013-26
pubmed: 11754834
Genes Cells. 2013 Mar;18(3):161-75
pubmed: 23356578
Int J Mol Sci. 2018 Aug 19;19(8):
pubmed: 30126252
Curr Opin Struct Biol. 1999 Jun;9(3):383-9
pubmed: 10361086
J Cell Sci. 2010 Oct 1;123(Pt 19):3303-15
pubmed: 20826458
Nat Rev Cancer. 2003 Mar;3(3):155-68
pubmed: 12612651
Am J Hum Genet. 2016 May 5;98(5):909-918
pubmed: 27132593
Eur J Cell Biol. 2014 Mar;93(3):98-105
pubmed: 24560403
Development. 2010 Jun;137(11):1907-17
pubmed: 20460369
Nature. 2011 Sep 21;478(7367):57-63
pubmed: 21937992
Front Genet. 2019 Oct 29;10:1060
pubmed: 31737043
Oncogene. 2007 Aug 13;26(37):5358-72
pubmed: 17694078
Clin Genet. 2005 Oct;68(4):287-301
pubmed: 16143014
Neuron. 2010 May 13;66(3):386-402
pubmed: 20471352
Nat Rev Genet. 2005 Jul;6(7):581-90
pubmed: 15951746
Hum Mol Genet. 2011 Mar 15;20(6):1182-96
pubmed: 21212100
Curr Genet. 2018 Oct;64(5):965-970
pubmed: 29470645
Hum Mutat. 2013 Nov;34(11):1472-6
pubmed: 23956177
Cell Cycle. 2015;14(13):2044-57
pubmed: 25942099
Ann Hum Genet. 1959 Apr;23(2):91-116
pubmed: 13637554
Science. 1974 Sep 6;185(4154):862-4
pubmed: 4843792
Arch Dis Child. 2013 Sep;98(9):707-13
pubmed: 23814088
J Neurosci. 2005 Dec 7;25(49):11300-12
pubmed: 16339025
Clin Genet. 2019 Oct;96(4):354-358
pubmed: 31290144
Cell. 2007 Dec 28;131(7):1248-59
pubmed: 18160036

Auteurs

Vincent Picher-Martel (V)

Department of psychiatry and neurosciences, Centre de recherche Cervo Brain Research Centre and CHU de Québec, Laval University, 2601 chemin de la canardière, Québec, Qc, G1J 2G3, Canada. vincent.picher-martel.1@ulaval.ca.

Yvan Labrie (Y)

Centre de recherche du CHU de Québec-Universtié Laval, Québec, Qc, Canada.

Serge Rivest (S)

Centre de recherche CHU de Québec- Universtié Laval, Québec, Qc, Canada.

Baiba Lace (B)

Department of Clinical Genetic, CHU de Québec- Université Laval, Québec, Qc, Canada.

Nicolas Chrestian (N)

Department of Paediatric Neurology, Paediatric Neuromuscular Disorder, Centre Mère Enfant Soleil, Laval University, Québec, Qc, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH